Ningbo MedicalSystem Biotechnology Co Ltd - Asset Resilience Ratio
Ningbo MedicalSystem Biotechnology Co Ltd (300439) has an Asset Resilience Ratio of 7.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Ningbo MedicalSystem Biotechnology Co Lt to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300439 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥265.90 Million | 7.27% |
| Total Liquid Assets | CN¥265.90 Million | 7.27% |
Asset Resilience Insights
- Limited Liquidity: Ningbo MedicalSystem Biotechnology Co Ltd maintains only 7.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ningbo MedicalSystem Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ningbo MedicalSystem Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ICON Public Limited Company
F:IJF |
Diagnostics & Research | 0.00% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for Ningbo MedicalSystem Biotechnology Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Ningbo MedicalSystem Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.35% | CN¥161.08 Million ≈ $23.57 Million |
CN¥3.71 Billion ≈ $542.17 Million |
+4.18pp |
| 2023-12-31 | 0.17% | CN¥6.00 Million ≈ $877.99K |
CN¥3.49 Billion ≈ $510.58 Million |
-2.06pp |
| 2022-12-31 | 2.24% | CN¥80.17 Million ≈ $11.73 Million |
CN¥3.58 Billion ≈ $524.40 Million |
-0.57pp |
| 2021-12-31 | 2.80% | CN¥100.70 Million ≈ $14.74 Million |
CN¥3.59 Billion ≈ $525.80 Million |
-2.87pp |
| 2017-12-31 | 5.67% | CN¥242.70 Million ≈ $35.51 Million |
CN¥4.28 Billion ≈ $626.09 Million |
-4.27pp |
| 2016-12-31 | 9.95% | CN¥340.00 Million ≈ $49.75 Million |
CN¥3.42 Billion ≈ $500.20 Million |
-10.10pp |
| 2015-12-31 | 20.04% | CN¥290.00 Million ≈ $42.44 Million |
CN¥1.45 Billion ≈ $211.71 Million |
-- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more